2022/11/21 ALA-1000 received notice of patent allowance from China National Intellectual Property Administration, Application No. 201780055635.3 Post author:alarpharm Post published:21 . 11 . 2022 Post category:Media releases You Might Also Like 2022/05/12 ALA-1000 Received notice of patent allowance from Director de Invenciones y Nuevas Tecnologías INDECOPI , Application No. 000487-2019/DIN. 13 . 5 . 2022 2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder 28 . 10 . 2021 2021/05/10 ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED), Application No.3,033,046 8 . 6 . 2021 2021/04/16 ALA-1000 Receive notice of allowance for patent registration from Korean Intellectual Property Office (Application No. 10-2019-7009185). 21 . 4 . 2021 2023/07/19 ALA-1300 Received the patent, LONG-ACTING INJECTABLE FORMULATIONS AND CRYSTALLINE FORMS OF BUPRENORPHINE DERIVATIVES , from Directorate General of Intellectual Property Rights (DGIP) of Indonesia, NO IDP 000 087828 B 26 . 7 . 2023
2022/05/12 ALA-1000 Received notice of patent allowance from Director de Invenciones y Nuevas Tecnologías INDECOPI , Application No. 000487-2019/DIN. 13 . 5 . 2022
2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder 28 . 10 . 2021
2021/05/10 ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED), Application No.3,033,046 8 . 6 . 2021
2021/04/16 ALA-1000 Receive notice of allowance for patent registration from Korean Intellectual Property Office (Application No. 10-2019-7009185). 21 . 4 . 2021
2023/07/19 ALA-1300 Received the patent, LONG-ACTING INJECTABLE FORMULATIONS AND CRYSTALLINE FORMS OF BUPRENORPHINE DERIVATIVES , from Directorate General of Intellectual Property Rights (DGIP) of Indonesia, NO IDP 000 087828 B 26 . 7 . 2023
